Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539175 | 0.92 | PTPN1 (0.64) | PTPN1HDAC8NR1H2NR1H3 | |
| SCHEMBL540060 | 0.92 | PTPN1 (0.64) | PTPN1HDAC8NR1H2NR1H3 | |
| SCHEMBL539676 | 0.86 | PTPN1 (0.58) | PTPN1HDAC8NR1H2NR1H3 | |
| SCHEMBL1151985 | 0.86 | PTPN1 (0.58) | PTPN1HDAC8NR1H2NR1H3 | |
| SCHEMBL6651228 | 0.83 | PTPN1 (0.62) | PTPN1HDAC8PDE4BPDE4DNR1H2 | |
| SCHEMBL29676960 | 0.82 | PTPN1 (0.68) | PTPN1HDAC8 | |
| SCHEMBL18793348 | 0.82 | PTPN1 (0.68) | PTPN1HDAC8 | |
| SCHEMBL20720251 | 0.82 | PTPN1 (0.68) | PTPN1HDAC8 | |
| SCHEMBL539738 | 0.82 | PTPN1 (0.54) | PTPN1HDAC8NR1H2NR1H3 | |
| SCHEMBL12849136 | 0.82 | PTPN1 (0.54) | PTPN1HDAC8NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | XDH, LPXN, F12 | PTPN1 1335/4885HDAC8 2794/4885PDE4B 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.